Investor Information

  • Corporate Updates - Psyence

Psyence Group Corporate Update

2023-08-02T14:35:09+02:00July 12, 2023|Press Releases, Investor Information|

Since Psyence’s corporate update issued in June 2022, the Company has made significant progress in its clinical trial programs and in upgrading its production facility and extraction capabilities. Psyence is executing on its strategy and is pleased to provide an update across the pillars of the business.

  • Psyence Corporate Update

Psyence Group Announces Closing Of Fourth Round Tranche Of Private Placement And Conversion Of Convertible Debt Note

2023-04-04T06:53:49+02:00April 4, 2023|Press Releases, Investor Information|

Psyence is pleased to announce that it has issued 9,043,038 common shares at a price of CAD$0.12 per common share for gross proceeds of CAD$1,085,164. This brings the total amount the Company has raised pursuant to the previously announced private placement to CAD $3.04 million ("Aggregate Proceeds").

  • PYSENCE_INGENU_FEATURE_2

Psyence Partners with iNGENū for Palliative Care Clinical Trial in Australia

2023-03-21T17:14:12+02:00March 21, 2023|Psychedelic News, Press Releases, Investor Information|

Psyence Australia Pty Ltd, has partnered with iNGENū Pty Ltd (iNGENū) to conduct Psyence’s previously announced clinical trial in palliative care. iNGENū is an Australian based, globally focused Contract Research Organization (CRO) with extensive experience working in the psychedelic pharmaceutical drug development and clinical research industry.

  • Newcourt to Acquire Psyence’s Clinical Trials Division

Psyence Announces Business Combination between Wholly Owned Subsidiary Psyence Biomed Corp. and Nasdaq listed Newcourt Acquisition Corp

2023-01-10T10:20:30+02:00January 10, 2023|Press Releases, Investor Information|

Psyence & Newcourt have entered into a definitive business combination agreement (the “Business Combination Agreement”) on January 9, 2023 with Psyence Biomed Corp (“Psyence Biomed”), a wholly owned subsidiary of Psyence, to create a public company (the “Combined Company”) leveraging natural psilocybin in the treatment of palliative care (the “Business Combination”). Psyence Biomed is Psyence’s clinical trial division.

Go to Top